2. Search Result
Search Result
Results for "

(±)-AMPA (Standard)

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

5

Natural
Products

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-14608R
    L-Glutamic acid (Standard)

    		Reference Standards Endogenous Metabolite iGluR Ferroptosis Apoptosis Neurological Disease
    L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases . IC50 & Target:DA . In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus .
    L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma .
    In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice .
    L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats .
    L-Glutamic acid (Standard)
  • HY-B0122R
    Topiramate (Standard)

    McN 4853 (Standard); RWJ 17021 (Standard)

    		 Reference Standards iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase Neurological Disease
    Topiramate (Standard) is the analytical standard of Topiramate. This product is intended for research and analytical applications. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate (Standard)
  • HY-100815BR
    (RS)-AMPA (Standard)

    (±)-AMPA (Standard)

    		 Reference Standards iGluR Neurological Disease
    (RS)-AMPA (Standard) is the analytical standard of (RS)-AMPA. This product is intended for research and analytical applications. (RS)-AMPA ((±)-AMPA) is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA does not interfere with binding sites for kainic acid or NMDA receptors .
    (RS)-AMPA (Standard)
  • HY-15068AR
    NBQX disodium (Standard)

    FG9202 disodium (Standard)

    		 iGluR Reference Standards Neurological Disease
    NBQX (disodium) (Standard) is the analytical standard of NBQX (disodium). This product is intended for research and analytical applications. NBQX disodium (FG9202 disodium) is a highly selective and competitive AMPA receptor antagonist. NBQX disodium has neuroprotective and anticonvulsant activity .
    NBQX disodium (Standard)
  • HY-14608AR
    L-Glutamic acid monosodium salt (Standard)

    		Reference Standards iGluR Apoptosis Ferroptosis Endogenous Metabolite Neurological Disease
    L-Glutamic acid (monosodium salt) (Standard) is the analytical standard of L-Glutamic acid (monosodium salt). This product is intended for research and analytical applications. L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases .
    L-Glutamic acid monosodium salt (Standard)
  • HY-90003AR
    Tianeptine sodium salt (Standard)

    		Reference Standards Opioid Receptor iGluR MMP PI3K Akt NF-κB Neurological Disease Inflammation/Immunology
    Tianeptine sodium salt (Standard) is the analytical standard of Tianeptine sodium salt (HY-90003A). This product is intended for research and analytical applications. Tianeptine sodium salt is an atypical antidepressant. Tianeptine sodium salt is a moderate-intensity agonist of the μ-opioid receptor (MOR), and to a lesser extent, is an agonist of the δ-opioid receptor (DOR). Tianeptine sodium salt is a glutamate modulator that can enhance AMPA receptor and antagonize NMDA receptor. Tianeptine sodium salt increases sensitivity of the α1 adrenergic receptor, which only manifests in chronic treatment. Tianeptine sodium salt exerts neuroprotective effects under stress/inflammation-induced conditions, exhibiting anti-inflammatory and antioxidant properties. Tianeptine sodium salt inhibits MMP-9 by suppressing the PI3K/Akt-mediated NF-κB pathway. Tianeptine sodium salt can be used to alleviate symptoms of depression and anxiety, but does not cause sedative effects.
    Tianeptine sodium salt (Standard)
  • HY-101165R
    Cyclothiazide (Standard)

    		Reference Standards iGluR GABA Receptor Neurological Disease
    Cyclothiazide (Standard) is the analytical standard of Cyclothiazide. This product is intended for research and analytical applications. Cyclothiazide is a positive allosteric modulator of ionotropic AMPA-type glutamate receptors. Cyclothiazide inhibits GABAA receptors. Cyclothiazide is frequently used to produce a fast inhibition of AMPA receptor desensitization and a much slower potentiation of the AMPA current. Cyclothiazide can potentiate responses to kainate in hippocampal neurons. Cyclothiazide has effects on glutamatergic neurotransmission. Cyclothiazide also induces epileptiform EEG activity accompanying behavioral seizures .
    Cyclothiazide (Standard)
  • HY-15068R
    NBQX (Standard)

    FG9202 (Standard)

    		 iGluR Reference Standards Neurological Disease
    NBQX (Standard) is the analytical standard of NBQX. This product is intended for research and analytical applications. NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity .
    NBQX (Standard)
  • HY-101363R
    1-BCP (Standard)

    Piperonylic acid piperidide (Standard)

    		 Reference Standards iGluR Neurological Disease
    1-BCP (Standard) is the analytical standard of 1-BCP. This product is intended for research and analytical applications. 1-BCP (Piperonylic acid piperidide) is a centrally active agent that modulates AMPA receptor gated currents. 1-BCP is a memory-enhancing agent .
    1-BCP (Standard)
  • HY-106467BR
    Caroverine hydrochloride (Standard)

    		Reference Standards iGluR Neurological Disease
    Caroverine (hydrochloride) (Standard) is the analytical standard of Caroverine (hydrochloride). This product is intended for research and analytical applications. Caroverine hydrochloride is a potent, competitive and reversible antagonist of NMDA and AMPA glutamate receptor. Caroverine hydrochloride is also an antioxidant and calcium-blocking agent that exhibits vasorelaxant action. Caroverine hydrochloride can be used for the research of inner ear tinnitus .
    Caroverine hydrochloride (Standard)
  • HY-15066R
    CNQX (Standard)

    FG9065 (Standard)

    		 iGluR Reference Standards Neurological Disease
    CNQX (Standard) is the analytical standard of CNQX. This product is intended for research and analytical applications. CNQX (FG9065) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX is a competitive non-NMDA receptor antagonist . CNQX blocks the expression of fear-potentiated startle in rats .
    CNQX (Standard)
  • HY-103234AR
    GYKI 52466 dihydrochloride (Standard)

    		Reference Standards iGluR Neurological Disease
    GYKI 52466 (dihydrochloride) (Standard) is the analytical standard of GYKI 52466 (dihydrochloride). This product is intended for research and analytical applications. GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research .
    GYKI 52466 dihydrochloride (Standard)
  • HY-N3298R
    Meranzin (Standard)

    		Reference Standards Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Meranzin (Standard) is the analytical standard of Meranzin. This product is intended for research and analytical applications. Meranzin is an absorbed bioactive compound from the Traditional Chinese Medicine (TCM) Chaihu-Shugan-San (CSS). Meranzin, isolated from leaves of Murraya exotica L., regulates the shared alpha 2-adrenoceptor and involves the AMPA-ERK1/2–BDNF signaling pathway. Meranzin has the potential for the prevention of the comorbidity of atherosclerosis and depression .
    Meranzin (Standard)
  • HY-17550R
    Sunifiram (Standard)

    DM-235 (Standard)

    		 Reference Standards iGluR Neurological Disease
    Sunifiram (Standard) is the analytical standard of Sunifiram. This product is intended for research and analytical applications. Sunifiram (DM-235) is an ampakine-like compound and an agonist of AMPA receptor with oral activity. Sunifiram can increase the release of acetylcholine in the rat cerebral cortex and exhibits potent cognitive enhancement effects with better nootropic activity compared to piracetam (HY-B0585). Sunifiram is promising for research in neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's disease (AD) .
    Sunifiram (Standard)
  • HY-110234R
    Topiramate D12 (Standard)

    McN 4853 D12 (Standard); RWJ 17021 D12 (Standard)

    		 Reference Standards iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase Neurological Disease
    Topiramate D12 (Standard) is the analytical standard of Topiramate D12. This product is intended for research and analytical applications. Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate D12 (Standard)
  • HY-W015309R
    Decanoic acid (Standard)

    		Reference Standards iGluR Tyrosinase c-Met/HGFR Glutaminase Neurological Disease Metabolic Disease Cancer
    Decanoic acid (Standard) is the analytical standard of Decanoic acid. This product is intended for research and analytical applications. Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .
    Decanoic acid (Standard)
  • HY-108599R
    DCP-LA (Standard)

    FR236924 (Standard)

    		 Reference Standards PKC CaMK Phosphatase Apoptosis Neurological Disease
    DCP-LA (Standard) is the analytical standard of DCP-LA. This product is intended for research and analytical applications. DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis[1][2][3].
    DCP-LA (Standard)
  • HY-108707R
    LY3130481 (Standard)

    		Reference Standards iGluR Neurological Disease
    LY3130481 (Standard) is the analytical standard of LY3130481 (HY-108707). This product is intended for research and analytical applications. LY3130481 is an orally available AMPA receptor antagonist, selectively inhibiting the IC50 value of AMPA/TARP γ-8 at 65 nM. LY3130481 has anticonvulsant, antiepileptic, and pain-relieving effects .
    LY3130481 (Standard)
  • HY-101216R
    Org-26576 (Standard)

    		Reference Standards iGluR Neurological Disease
    Org-26576 (Standard) is the analytical standard of Org-26576 (HY-101216). This product is intended for research and analytical applications. Org-26576 is a AMPA receptor positive allosteric modulator.
    Org-26576 (Standard)
  • HY-103230R
    IEM-1460 (Standard)

    		Reference Standards iGluR Neurological Disease
    IEM-1460 (Standard) is the analytical standard of IEM-1460 (HY-103230). This product is intended for research and analytical applications. IEM-1460 blocks both AMPA and NMDA glutamate receptor with anticonvulsant effect in vivo .
    IEM-1460 (Standard)
  • HY-103228R
    GYKI 53655 hydrochloride (Standard)

    LY300168 hydrochloride (Standard)

    		 Reference Standards iGluR Neurological Disease
    GYKI 53655 hydrochloride (Standard) is the analytical standard of GYKI 53655 hydrochloride (HY-103228). This product is intended for research and analytical applications. GYKI 53655 (LY300168) hydrochloride is an α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) antagonist.
    GYKI 53655 hydrochloride (Standard)
  • HY-15067R
    DNQX (Standard)

    FG 9041 (Standard)

    		 iGluR Reference Standards Cancer
    DNQX (Standard) is the analytical standard of DNQX. This product is intended for research and analytical applications. DNQX (FG 9041), a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively) .
    DNQX (Standard)
  • HY-101528R
    IDRA 21 (Standard)

    		iGluR Reference Standards Neurological Disease
    IDRA 21 (Standard) is the analytical standard of IDRA 21 (HY-101528). This product is intended for research and analytical applications. IDRA 21 is a positive and orally active modulator of the AMPA receptor. IDRA 21 facilitates excitatory neurotransmission via GluR1/2 receptors. IDRA 21 has the potential for the research of cognitive/memory disorders, including those associated with aging .
    IDRA 21 (Standard)
  • HY-109046R
    Tulrampator (Standard)

    CX-1632 (Standard); S-47445 (Standard)

    		 Reference Standards iGluR mTOR Neurological Disease
    Tulrampator (Standard) is the analytical standard of Tulrampator (HY-109046). This product is intended for research and analytical applications. Tulrampator (S-47445) is an orally active selective AMPA receptor modulator. Tulrampator possesses procognitive, enhancing synaptic plasticity, anti-depressant-anxiolytic-like, procognitive and potential neuroprotective properties. Tulrampator can be used for research of alzheimer’s disease and in major depressive disorder .
    Tulrampator (Standard)
  • HY-108497R
    L-803087 (Standard)

    		Reference Standards Somatostatin Receptor Neurological Disease Cancer
    L-803087 (Standard) is the analytical standard of L-803087 (HY-108497). This product is intended for research and analytical applications. L-803087 is a potent and selective somatostatin sst4 receptor agonist with a Ki of 0.7 nM. L-803087 is >280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .
    L-803087 (Standard)
  • HY-N0660R
    Jujuboside B (Standard)

    		Reference Standards ERK p38 MAPK Akt PI3K 11β-HSD STING VEGFR Ferroptosis Autophagy Apoptosis Keap1-Nrf2 Caspase PARP AMPK Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Jujuboside B (Standard) is the analytical standard of Jujuboside B. This product is intended for research and analytical applications. Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes.
    Jujuboside B (Standard)

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: